Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Futubull > Quotes > AMGN Amgen > Detailed Quotes

AMGN Amgen

Watchlist
243.300
-2.130-0.87%
Close 06/30 16:00 ET
243.30000.00%
Post Mkt Price 06/30 16:15 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
245.000
Open
244.170
Turnover
733.48M
Low
240.730
Pre Close
245.430
Volume
3.02M
Market Cap
129.97B
P/E(TTM)
24.02
52wk High
257.970
Shares
534.20M
P/E(Static)
23.67
52wk Low
195.376
Float Cap
129.60B
Bid/Ask %
0.00%
Historical High
263.971
Shs Float
532.68M
Volume Ratio
0.97
Historical Low
8.531
Dividend TTM
7.22
Div Yield TTM
10000
P/B
141.87
Dividend LFY
2.97%
Div Yield LFY
4110.15%
Turnover Ratio
0.57%
Amplitude
1.74%
Avg Price
243.135
Lot Size
1
Float Cap
129.60B
Bid/Ask %
0.00%
Historical High
263.971
Shs Float
532.68M
Volume Ratio
0.97
Historical Low
8.531
Dividend TTM
7.22
P/B
141.87
Dividend LFY
2.97%
Turnover Ratio
0.57%
Amplitude
1.74%
Avg Price
243.135
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
CEO: Bradway, Robert A.
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top